Dr. Tracey L. Mclaughlin, MD
Endocrinology & Diabetes (Endocrinology, Diabetes & Metabolism Physician)
300 Pasteur Dr
Stanford, CA 94305
Who else practices at this address →
Santa Clara County includes mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of California, San Francisco School of Medicine (1994)
- Years since graduation
- 32
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 79
Licensed in California since 1995, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1994Medical school: University of California, San Francisco School of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Endocrinology, Diabetes & Metabolism Physician primary
CA license A55287 (first issued 1995; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Stanford Health Care Stanford, CA
Medical groups
- Stanford Health Care (3,122 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 79
- Services billed
- 251
- Patients’ average age
- 64
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 148 | 18 |
| Established patient office or other outpatient visit, 40-54 minutes | 131 | 63 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 84 | 40 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 15 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Mounjaro (tirzepatide) Other prescribers in Stanford, CA | 46 |
| Ozempic (semaglutide) Other prescribers in Stanford, CA | 43 |
| Trulicity (dulaglutide) Other prescribers in Stanford, CA | 39 |
| Januvia (sitagliptin phosphate) Other prescribers in Stanford, CA | 36 |
| Glipizide Other prescribers in Stanford, CA | 35 |
| Jardiance (empagliflozin) Other prescribers in Stanford, CA | 32 |
| Alendronate Sodium Other prescribers in Stanford, CA | 30 |
| Pravastatin Sodium Other prescribers in Stanford, CA | 29 |
| Rosuvastatin Calcium Other prescribers in Stanford, CA | 28 |
| Lantus Solostar (insulin glargine,hum.rec.anlog) Other prescribers in Stanford, CA | 27 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 10 payments worth $7,790 in total to this clinician.
| Regeneron Pharmaceuticals, Inc. | $7,194 |
|---|---|
| Dexcom, Inc. | $550 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $46.61 |
| Consulting Fee | $6,793 |
|---|---|
| Speaking at a medical education program | $550 |
| Travel and Lodging | $369 |
| Food and Beverage | $78.57 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Regeneron Pharmaceuticals, Inc. Mar 7, 2025 | Consulting Fee | $5,363 |
| Regeneron Pharmaceuticals, Inc. Mar 7, 2025 | Consulting Fee | $1,430 |
| Dexcom, Inc. Sep 16, 2025 | Speaking at a medical education program DEXCOM STELO GLUCOSE BIOSENSOR | $550 |
| Regeneron Pharmaceuticals, Inc. Mar 7, 2025 | Travel and Lodging travel to UNIVERSAL CITY, CA · in-kind | $269 |
| Regeneron Pharmaceuticals, Inc. Mar 7, 2025 | Travel and Lodging travel to UNIVERSAL CITY, CA · in-kind | $51.35 |
| Regeneron Pharmaceuticals, Inc. Mar 7, 2025 | Travel and Lodging travel to UNIVERSAL CITY, CA · in-kind | $48.99 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 4 companies. The companies reported $544,129 in research payments for these studies, mostly to the institutions running them.
- Study name not reported
Eli Lilly and Company - PAS576
Recordati_rare_diseases_inc. - Ertugliflozin: Cardioprotective Effects on Epicardial Fat
Merck Sharp & Dohme LLC - Defining the metabolic and molecular basis for interindividual variability in postprandial glucose responses
Dexcom, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.